EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter “EditForce”) has entered into a License Agreement (hereinafter “Agreement”) with Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, Representative Director: Hiroaki Ueno; hereinafter “MTPC”) to research, develop and commercialize potential gene therapy products for a specific target disease in the field of CNS by utilizing EditForce’s proprietary PPR protein platform technology. Logo of EditForce, Inc.: https://kyodonewsprwire.jp/prwfile/release/M107232/202206242954/_prw_PI1fl_09s1955H.jpg In this alliance, MTPC and EditForce aim to create potential novel pharmaceuticals for the specific CNS...